{
  "docId": "019de514-4d4c-7369-a2bf-f736423e3911",
  "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53",
  "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides",
  "authorId": "imara",
  "authorName": "Enliven Therapeutics / Imara",
  "documentKindSlug": "press-release",
  "documentKindLabel": "Press release",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 45,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "executive_summary",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "Includes a line chart showing treatment duration and a pie chart showing patient outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/10",
  "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911",
  "deckJsonHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911.json",
  "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.52,
        "y": 0.82
      },
      "kind": "callout",
      "text": "10% overall share (by patients) equates to >$1 billion market opportunity in the U.S. alone",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7209fd09-6452-4ab2-8dce-6fa27df75dff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.05,
        "y": 0.82
      },
      "kind": "callout",
      "text": "CML is a chronic disease requiring many years (even decades) of treatment",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99d78c26-9862-4d58-8672-ed9ebd41d944",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.05,
        "y": 0.5
      },
      "kind": "chart",
      "text": "Treatment Duration for SOC by Line of Therapy",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2ce68a1-c93b-4593-8ab8-8740260c55e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.52,
        "y": 0.5
      },
      "kind": "chart",
      "text": "Current Outcomes in CML",
      "attrs": null,
      "subkind": "pie",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b11d52d1-5478-421d-9ed7-3b786f0ac37d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Growing patient population due to improved survival, requiring some patients to be on TKIs for decades. Existing approved drugs have liabilities as chronic therapy. Five approved drugs drive annual sales of >$6B.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d125870-6d87-42c3-8ad6-b6a4319f8897",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.52,
        "y": 0.2
      },
      "kind": "list",
      "text": "New drugs with better tolerability and efficacy profiles. Additional focus on deeper molecular responses. Chronic nature allows doctors to freely switch between therapies.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f000c87e-18f8-4976-988e-a91c531fa8ba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "Current Market",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ff7f71e-059f-43bc-8b54-5908961aa53e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.52,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "Our Vision",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe613804-8af4-43bd-8c0c-67e697ff5858",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Develop BCR/ABL Mutations. Develop other molecular abnormalities. Assumes current branded pricing. CML = Chronic Myeloid Leukemia. SOC = Standard of care. TFR = Treatment free remission. TKI = Tyrosine kinase inhibitor. Reference: Baccarani M and Gale RP. Leukemia. 2021; 35:2199-2204.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2845f656-c5de-4c28-84bc-9e304303854a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Evolving Chronic Myeloid Leukemia Market Dynamics",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aea5c9ed-7a74-4c37-ba78-e001ee3afde3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 9,
      "beatId": "f1c5daaa-0597-4f81-b694-1845468beefb",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The document identifies a significant need for better treatment options for chronic myeloid leukemia and other cancers.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 29,
      "from": 10,
      "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}